View Filing Data

Document and Entity Information - USD ($)	9 Months Ended
Document and Entity Information - USD ($)	Sep. 30, 2013	Oct. 31, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Filer Category	Accelerated Filer
Entity Public Float	$ 0
Entity Common Stock, Shares Outstanding		36,367,254
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 172,561	$ 141,666
Accounts receivable	30,093	96,043
Inventories	16,325	15,161
Deferred tax assets, net	1,264	1,264
Income tax receivable, net	588	0
Prepaid expenses and other current assets	13,184	9,213
Total current assets	234,015	263,347
Property, plant and equipment, net	263,056	241,764
In process research and development	41,800	41,800
Goodwill	14,294	5,502
Intangible assets, net	30,771	0
Deferred tax assets, net	11,087	11,087
Other assets	441	730
Total assets	595,464	564,230
Current liabilities:
Accounts payable	29,018	31,297
Accrued expenses and other current liabilities	1,359	1,603
Accrued compensation	18,421	22,726
Contingent purchase consideration, current portion	1,326	0
Long-term indebtedness, current portion	4,470	4,470
Deferred revenue	2,038	1,811
Total current liabilities	56,632	61,907
Contingent purchase consideration, net of current portion	15,255	0
Long-term indebtedness, net of current portion	54,952	58,304
Other liabilities	1,768	1,891
Total liabilities	128,607	122,102
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,714,299 shares issued and 36,311,141 shares outstanding at September 30, 2013; 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012	37	36
Additional paid-in capital	240,372	230,964
Treasury stock, at cost, 403,158 common shares at September 30, 2013 and December 31, 2012	(5,906)	(5,906)
Accumulated other comprehensive loss	(3,502)	(4,129)
Retained earnings	236,305	220,393
Total Emergent BioSolutions Inc. stockholders' equity	467,306	441,358
Noncontrolling interest in subsidiaries	(449)	770
Total stockholders' equity	466,857	442,128
Total liabilities and stockholders' equity	$ 595,464	$ 564,230

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2013	Dec. 31, 2012
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	36,714,299	36,272,550
Common stock, shares outstanding (in shares)	36,311,141	35,869,392
Treasury Stock ( in Shares)	403,158	403,158

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Product sales	$ 76,297	$ 54,011	$ 172,252	$ 141,529
Contracts and grants	12,805	12,581	42,386	45,753
Total revenues	89,102	66,592	214,638	187,282
Operating expenses:
Cost of product sales	20,063	10,230	42,706	30,927
Research and development	28,937	27,390	89,939	84,281
Selling, general and administrative	21,955	19,155	62,484	56,542
Impairment of in-process research and development	0	0	0	9,600
Income from operations	18,147	9,817	19,509	5,932
Other income (expense):
Interest income	88	55	121	103
Interest expense	0	0	(14)	0
Other income (expense), net	58	(16)	93	1,745
Total other income (expense)	146	39	200	1,848
Income before provision for income taxes	18,293	9,856	19,709	7,780
Provision for income taxes	4,802	4,236	4,667	4,639
Net income	13,491	5,620	15,042	3,141
Net loss attributable to noncontrolling interest	0	997	871	4,276
Net income attributable to Emergent BioSolutions Inc.	$ 13,491	$ 6,617	$ 15,913	$ 7,417
Income per share - basic	$ 0.37	$ 0.18	$ 0.44	$ 0.21
Income per share - diluted	$ 0.36	$ 0.18	$ 0.44	$ 0.20
Weighted-average number of shares - basic	36,272,579	36,202,801	36,129,183	36,144,242
Weighted-average number of shares - diluted	37,015,529	36,670,094	36,504,230	36,424,630

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements of Comprehensive Income (unaudited) [Abstract]
Net income attributable to Emergent BioSolutions Inc.	$ 13,491	$ 6,617	$ 15,913	$ 7,417
Foreign currency translations, net of tax	11	(652)	627	(588)
Comprehensive income	$ 13,502	$ 5,965	$ 16,540	$ 6,829

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income	$ 15,042	$ 3,141
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	8,459	8,417
Depreciation and amortization	13,547	7,679
Current and deferred income taxes	4,667	8,679
Non-cash development expenses from joint venture	(348)	3,163
Impairment of in-process research and development	0	9,600
Change in fair value of contingent value rights	0	(3,005)
Change in fair value of contingent purchase consideration	349	0
Excess tax benefits from stock-based compensation	(1,949)	(1,482)
Other	(19)	(39)
Changes in operating assets and liabilities:
Accounts receivable	65,950	57,006
Inventories	(1,164)	(3,584)
Income taxes	(6,927)	(1,597)
Prepaid expenses and other assets	(3,532)	(1,544)
Accounts payable	(1,622)	(3,495)
Accrued expenses and other liabilities	(240)	301
Accrued compensation	(4,164)	(4,790)
Deferred revenue	278	212
Net cash provided by operating activities	88,327	78,662
Cash flows from investing activities:
Purchases of property, plant and equipment	(34,420)	(40,943)
Proceeds from sale of assets	0	11,765
Proceeds from maturity of investments	0	1,966
Acquisition of Healthcare Protective Products Division	(24,120)	0
Net cash used in investing activities	(58,540)	(27,212)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	0	12,946
Issuance of common stock subject to employee equity plans	2,505	495
Excess tax benefits from stock-based compensation	1,949	1,482
Principal payments on long-term indebtedness	(3,352)	(9,386)
Contingent value right payment	0	(1,748)
Purchase of treasury stock	0	(1,457)
Restricted cash	0	220
Net cash provided by financing activities	1,102	2,552
Effect of exchange rate changes on cash and cash equivalents	6	(2)
Net increase (decrease) in cash and cash equivalents	30,895	54,000
Cash and cash equivalents at beginning of period	141,666	143,901
Cash and cash equivalents at end of period	$ 172,561	$ 197,901

Summary of significant accounting policies	9 Months Ended
Summary of significant accounting policies	Sep. 30, 2013
Summary of significant accounting policies [Abstract]
Summary of significant accounting policies	1. Summary of significant accounting policies Basis of presentation and consolidation The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2013 and the results of operations, comprehensive income and cash flows for the three and nine months ended September 30, 2013 and 2012. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC, during the three and nine months ended September 30, 2013, except for the addition of the Company's policy for multiple element revenue-generating arrangements and its revenue recognition policy related to the Company's contract with the Biomedical Advanced Research and Development Authority ("BARDA") to establish a Center for Innovation in Advanced Development and Manufacturing ("CIADM") and the addition of a policy for contingent purchase consideration obligations. Revenue recognition The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's selling price and is recognized in full when the criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company. The Company's contract with the BARDA to establish a CIADM is a service arrangement that includes multiple elements. The CIADM contract requires the Company to provide a flexible infrastructure to supply medical countermeasures to the U.S. government over the contract period and includes such items as construction and facility design, workforce development and licensure of a pandemic flu vaccine. Since none of the individual elements by themselves satisfy the purpose of the contract, the Company has concluded that the CIADM contract elements cannot be separated as they do not have stand-alone value to the U.S. government. Therefore, the Company has concluded that there is a single unit of accounting associated with the CIADM contract. The Company recognizes revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzes the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue is required. Changes in estimates attributed to modifications in the estimate of total payments to be received are recorded prospectively. Contingent purchase consideration obligations In accordance with the terms of the Company's August 2013 acquisition of the Healthcare Protective Products Division ("HPPD"), a division of Bracco Diagnostics Inc. ("Bracco"), the Company has committed to make potential payments to Bracco based on achievement of certain net sales thresholds of RSDL through 2028. The Company records this obligation at fair value. Contingent purchase consideration is based on a percentage of future net RSDL sales. The fair value model used to calculate this obligation is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales. The inputs the Company uses for determining the fair value of the contingent purchase consideration are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales. Any future increase in the fair value of the contingent purchase consideration obligation is based on an increased likelihood that the underlying net sales will be achieved and the associated payment or payments which will therefore become due and payable, which will result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of the contingent purchase consideration obligation will result in a reduction in cost of product sales.

Acquisition of Healthcare Protective Products Division

9 Months Ended

Sep. 30, 2013

Acquisition of Healthcare Protective Products Division [Abstract]

Acquisition of Healthcare Protective Products Division [Text Block]

2. Acquisition of Healthcare Protective Products Division

On August 1, 2013, the Company acquired substantially all of the assets of the HPPD, a division of Bracco, for approximately $24.1 million in cash along with contingent purchase consideration obligations to Bracco. The assets acquired in this acquisition include HPPD's product, RSDL, and a majority of the customer and distributor agreements associated with RSDL. In addition, as part of the acquisition, the Company will acquire from Bracco, for approximately $1.8 million, the remaining HPPD assets, which primarily include manufacturing equipment. These remaining HPPD assets and the associated liability, have been included in the Company's consolidated balance sheets as of September 30, 2013. The Company anticipates the acquisition of the remaining assets will occur during the fourth quarter of 2013. The acquisition diversifies the Biodefense segment by adding product sales from RSDL.

The contingent purchase consideration obligations is based on a percentage of RSDL net sales, ranging from 5-10%, for the period August 1, 2013 through July 31, 2028. At August 1, 2013, the contingent purchase consideration obligation was recorded at a fair value of $16.2 million. The Level 3 fair value of these obligations are based on management's assessment of the potential future realization of the contingent purchase consideration payments. This assessment is based on inputs that have no observable market. The obligation is measured using the income approach (a discounted cash flow model).

The total preliminary purchase price is summarized below:

(in thousands)
Amount of cash paid to Bracco Diagnostics Inc.	$	24,120
Fair value of contingent purchase consideration		16,232
Total estimated purchase price	$	40,352

The table below summarizes the preliminary allocation of the purchase price based upon fair values of assets acquired and liabilities assumed at August 1, 2013. This preliminary allocation is based upon information that was available to management at the time the financial statements were prepared. Accordingly, the allocation may change. The allocation is not yet final pending the valuation of acquired property, plant and equipment, intangible assets and pre-acquistion contingent liabilites, as well as the assessment of amoritzation periods for intangible assets.

(in thousands)
Acquired intangible assets	$	31,549
Goodwill		8,792
Other		11
Total estimated purchase price	$	40,352

A substantial portion of the assets acquired from Bracco consisted of intangible assets associated with the RSDL product. As of the date of acquisition, the Company has recorded intangible assets of approximately $28.1 million related to RSDL and $3.5 million related to a manufacturing agreement with Bracco. For each of the three and nine month periods ended September 30, 2013, the Company recorded $779,000 in amortization for intangible assets, which have been recorded in cost of product sales within the Company's Biodefense segment.

The Company recorded approximately $8.8 million in goodwill related to the HPPD acquisition representing the purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired. This goodwill is included in the Company's Biodefense segment. None of the goodwill generated from the HPPD acquisition is expected to be deductible for tax purposes.

The Company has incurred transaction costs related to the HPPD acquisition of approximately $283,000 and $800,000, respectively, for the three and nine month periods ended September 30, 2013, which have been recorded in selling, general and administrative expenses within the Company's Biodefense segment.

The Company has determined that the transaction was not significant, and as such no proforma disclosures were required.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Fair value measurements

9 Months Ended

Sep. 30, 2013

Fair value measurements [Abstract]

Fair value measurements

3. Fair value measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, include:

Level 1 — Observable inputs for identical assets or liabilities such as quoted prices in active markets;

Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 — Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At September 30, 2013
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)	$	32,723	$	-	$	-	$	32,723
Total assets	$	32,723	$	-	$	-	$	32,723

Liabilities:
Contingent purchase consideration	$	-	$	-	$	16,581	$	16,581
Total liabilities	$	-	$	-	$	16,581	$	16,581

	At December 31, 2012
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)	$	42,720	$	-	$	-	$	42,720
Total assets	$	42,720	$	-	$	-	$	42,720

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

During the periods ended September 30, 2013 and December 31, 2012, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.

As of September 30, 2013 and 2012, the Company had no assets or liabilities measured at fair value using significant unobservable inputs (Level 3) except for contingent value right ("CVR") and contingent purchase consideration obligations.

The fair value of the CVR obligations is based on management's assessment of certain development and collaboration milestones, which are inputs that have no observable market (Level 3). The obligation is measured using a discounted cash flow model. During the nine months ended September 30, 2012, the Company recorded a decrease in the CVR obligations of $3.0 million due to Pfizer ceasing development of programs related to the CVR milestones and made a $1.7 million CVR payment under the Company's agreement with Abbott. The adjustment to fair value is classified in the Company's statement of operations as research and development expense within the Company's Biosciences segment.

The fair value of contingent purchase consideration obligations are based on management's assessment of changes as a result of adjustments to the discount rates and updates in the assumed and actual achievement of net sales for RSDL, which are inputs that have no observable market (Level 3). For the three and nine months ended September 30, 2013, the contingent purchase consideration increased by $349,000 primarily due to an adjustment to the discount rate and the timing of RSDL sales. The adjustment to fair value is classified in the Company's statement of operations as cost of product sales within the Company's Biodefense segment.

The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended September 30, 2013 and December 31, 2012:

(in thousands)
Balance at January 1, 2012	$	4,753
Expense (income) included in earnings		(3,005	)
Expense (income) included in comprehensive income (loss)		-
Settlements		(1,748	)
Purchases, sales, issuances and settlements		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2012	$	-
Expense included in earnings		349
Expense (income) included in comprehensive income (loss)		-
Settlements		-
Purchases, sales and issuances		16,232
Transfers in/(out) of Level 3		-
Balance at September 30, 2013	$	16,581

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as described above, from those measured at fair value on a nonrecurring basis. For the nine months ended September 30, 2013, no assets or liabilities were measured at fair value on a nonrecurring basis. For the year ended December 31, 2012, the Company's SBI-087 in-process research and development ("IPR&D") asset, which was categorized as a Level 3 fair value measurement, was the only asset or liability measured at fair value on a nonrecurring basis (see Note 5).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

9 Months Ended

Sep. 30, 2013

Inventories [Abstract]

Inventories

4. Inventories

Inventories consist of the following:

	September 30,		December 31,
(in thousands)	2013		2012
Raw materials and supplies	$	2,353	$	2,733
Work-in-process		7,299		9,813
Finished goods		6,673		2,615
Total inventories	$	16,325	$	15,161

In-process research and development and goodwill	9 Months Ended
In-process research and development and goodwill	Sep. 30, 2013
In-process research and development and goodwill [Abstract]
In-process research and development and goodwill	5. In-process research and development and goodwill During the nine months ended September 30, 2012, Pfizer terminated its development program with respect to the Company's SBI-087 product candidate. The Company considered this termination a potential indicator of impairment of the related SBI-087 IPR&D asset, and assessed the fair value of this asset. As part of the assessment, the Company considered the impact of Pfizer's decision, along with the Company's decision to no longer pursue further development of this asset due to reduced overall probability of success and increased development costs for the product candidate. As a result, the Company recorded an impairment charge of $9.6 million during the nine months ended September 30, 2012, which represented the entire carrying value of the SBI-087 IPR&D asset. This charge is classified in the Company's statement of operations as impairment of in-process research and development, within the Company's Biosciences segment. As a result of the impairment of the SBI-087 IPR&D asset, the Company also performed an analysis of the Biosciences therapeutic reporting unit at September 30, 2012, and concluded that the $5.5 million in goodwill was not more likely than not impaired and therefore an interim impairment analysis was deemed unnecessary. As of September 30, 2013 and December 31, 2012, the Company had goodwill assocated with the Biosciences Therapurtic reporting unit of $5.5 million.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Stockholders' equity

9 Months Ended

Sep. 30, 2013

Stockholders' equity [Abstract]

Stockholders' equity

6. Equity awards

The following is a summary of stock option award activity under the Second Amended and Restated Emergent BioSolutions Inc., 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan"):

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		3,550,842		$	17.07		53,156	$	8.86	$	4,801,378
Granted		926,610			14.84		-
Exercised		(185,173	)		11.57		-
Forfeited		(392,588	)		18.53		-
Outstanding at September 30, 2013		3,899,691		$	16.66		53,156	$	8.86	$	12,844,035
Exercisable at September 30, 2013		2,363,426		$	16.92		53,156	$	8.86	$	7,580,433

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		715,609		$	18.41	$	11,478,368
Granted		463,304			14.84
Vested		(329,877	)		14.81
Forfeited		(70,896	)		15.84
Outstanding at September 30, 2013		778,140		$	16.33	$	14,823,567

During the nine months ended September 30, 2013, the Company corrected an immaterial prior period classification error for the nine months ended September 30, 2012 of approximately $3.0 million. This immaterial error related to the cash flow presentation of the excess tax benefit attributed to the exercise of non-qualified stock options and restricted stock units and had no impact on the Company's consolidated cash flows, consolidated statements of operations and comprehensive income or the consolidated balance sheets. The correction of the error is reflected as a reduction of originally reported operating cash flow from operating activities and an increase in originally reported cash flow from financing activities.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Variable interest entities

9 Months Ended

Sep. 30, 2013

Variable interest entities [Abstract]

Variable interest entities

7. Variable interest entities

In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). The Company has a 51% equity interest in OETC. In February 2013, the Company published data from the Phase IIb clinical trial which showed its tuberculosis vaccine product candidate did not confer statistically significant protection for the tuberculosis disease or infection in infants from those vaccinated at birth with the Baccile Calmette-Guerin vaccine. As a result of this clinical trial data, the Company has ceased development work on this product candidate and expects future funding of OETC to be minimal while the OETC entity is liquidated.

The Company evaluates its variable interests in OETC on a quarterly basis and has determined that it is the primary beneficiary as it has directed the activities of OETC that most significantly impact OETC's economic performance and, as a result, will absorb the majority of expected losses. Accordingly, the Company consolidates OETC. As of September 30, 2013 and 2012, respectively, assets of $308,000 and $1.6 million, respectively, and liabilities of $243,000 and $2.8 million, respectively, related to OETC were included within the Company's consolidated balance sheets. During the three months ended September 30, 2013, OETC did not incur any net losses. During the nine months ended September 30, 2013, OETC incurred a net loss of $1.8 million, of which, $905,000 is included in the Company's consolidated statement of operations. During the three and nine months ended September 30, 2012, OETC incurred net losses of $2.0 million and $8.5 million, respectively, of which $1.0 million and $4.3 million, respectively, are included in the Company's consolidated statement of operations.

In conjunction with the establishment of OETC, the Company granted a put option to Oxford and certain Oxford researchers whereby the Company may be required to acquire all of the OETC shares held by Oxford and the Oxford researchers at the fair market value of the underlying shares. This put option is contingent upon the satisfaction of a number of conditions that must exist or occur subsequent to the granting by the European Commission of marketing authorization for the OETC-sponsored tuberculosis vaccine product candidate. The Company accounts for the put option in accordance with the accounting provisions related to derivatives and distinguishing liabilities from equity. In accordance with these provisions, the Company has determined that the put option had no value as of September 30, 2013.

The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:

	Emergent		Noncontrolling
(in thousands)	BioSolutions Inc.		Interests			Total
Stockholders' equity at December 31, 2012	$	441,358	$	770		$	442,128
Non-cash development expenses from variable interest entities		-		(348	)		(348	)
Net income (loss)		15,913		(871	)		15,042
Other		10,035		-			10,035
Stockholders' equity at September 30, 2013	$	467,306	$	(449	)	$	466,857

Collaboration Agreements	9 Months Ended
Collaboration Agreements	Sep. 30, 2013
Collaboration Agreements [Abstract]
Collaboration Agreements	8. Collaboration agreements Abbott Laboratories In August 2009, Trubion Pharmaceuticals, Inc. ("Trubion"), which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott Laboratories ("Abbott"), for the joint worldwide development and commercialization of otlertuzumab (formerly TRU-016). The collaboration agreement was terminated on March 20, 2012 and all rights to otlertuzumab and other CD37-directed protein therapeutics under the collaboration agreement reverted back to the Company. During the nine months ended September 30, 2012, respectively, the Company recorded revenue of $2.7 million for collaborative research and development services pursuant to the Abbott agreement, which is included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. There was no revenue for the three months ended September 30, 2013 and 2012 and the nine months ended September 30, 2013. Pfizer Inc. In December 2005, Trubion entered into an agreement (the "Pfizer Agreement") with Wyeth Pharmaceuticals, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In May 2011, the Company and Pfizer entered into a third amendment to the Pfizer Agreement (the "Biosimilar Amendment") in which the Company released certain restrictions related to the development and commercialization of biosimilar CD20 antibodies. Under the terms of this amendment, the Company is entitled to receive royalty payments in the low-single digits on net sales of certain Pfizer biosimilar products directed to CD20, subject to the satisfaction of specified conditions. In September 2012, the Pfizer Agreement was terminated. The Company's right to receive royalty payments under the Biosimilar Amendment survives termination of the Pfizer Agreement. During the three and nine months ended September 30, 2012, the Company recorded revenue of $356,000 and $1.2 million for research and development services pursuant to the Pfizer agreement, which is included in the Company's statement of operations as contracts and grants revenue within the Company's Biosciences segment. There was no revenue for the three and nine months ended September 30, 2013.

Restructuring

9 Months Ended

Sep. 30, 2013

Restructuring [Abstract]

Restructuring

9. Restructuring

In February 2013, the Company adopted a plan to restructure the operations of Emergent Product Development UK Limited ("EPDU") and OETC due to the results of the Phase IIb clinical trial for the Company's tuberculosis vaccine product candidate. The Company completed this restructuring as of June 30, 2013, except for the payment of certain termination benefit obligations that remain payable as of September 30, 2013.

The restructuring plan included a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. These costs, which are included in selling, general and administrative expense in the Company's statement of operations and are included within the Biosciences segment, are detailed below:

	Incurred during		Incurred during
	the three months		the nine months		Total Expected
(in thousands)	ended September 30, 2013		ended September 30, 2013		to be Incurred
Termination benefits	$	-	$	2,114	$	2,114
Contract termination costs		-		431		431
Other costs		-		261		261
Total	$	-	$	2,806	$	2,806

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

				Contract
	Termination			Termination			Other
(in thousands)	Benefits			Costs			Costs			Total
Balance at December 31, 2012	$	-		$	-		$	-		$	-
Expenses incurred		2,114			431			134			2,679
Amount paid		(1,660	)		(431	)		(134	)		(2,225	)
Other adjustments		-			-			-			-
Balance at September 30, 2013	$	454		$	-		$	-		$	454

Business Interruption Insurance Recovery	9 Months Ended
Business Interruption Insurance Recovery	Sep. 30, 2013
Business Interruption Insurance Recovery [Abstract]
Business Interruption Insurance Recovery [Text Block]	10. Business interruption insurance recovery During the nine months ended September 30, 2012, the Company recorded $1.7 million from an insurance recovery related to a power outage at its Lansing, Michigan facility. The insurance recovery is classified in the Company's statement of operations as other income (expense), net.

Earnings per share

9 Months Ended

Sep. 30, 2013

Earnings per share [Abstract]

Earnings per share

11. Earnings per share

The following table presents the calculation of basic and diluted net income per share:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except share and per share data)	2013		2012		2013		2012
Numerator:
Net income	$	13,491	$	6,617	$	15,913	$	7,417

Denominator:
Weighted-average number of shares—basic		36,272,579		36,202,801		36,129,183		36,144,242
Dilutive securities—equity awards		742,950		467,293		375,047		280,388
Weighted-average number of shares—diluted		37,015,529		36,670,094		36,504,230		36,424,630

Income per share-basic	$	0.37	$	0.18	$	0.44	$	0.21
Income per share-diluted	$	0.36	$	0.18	$	0.44	$	0.20

Stock options with exercise prices in excess of the average per share closing price during the period are not considered in the calculation of fully diluted earnings per share. For the three and nine month periods ended September 30, 2013, approximately 1.4 million and 1.5 million stock options, respectively, were excluded from the calculation of diluted earnings per share. For the three and nine month periods ended September 30, 2012, approximately 3.0 million and 2.9 million stock options, respectively, were excluded from the calculation of diluted earnings per share.

Segment information

9 Months Ended

Sep. 30, 2013

Segment information [Abstract]

Segment information

12. Segment information

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or operating divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are composed of business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products and product candidates with different development processes.

The Biodefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets oncology indications, and consists of two business units, therapeutics and vaccines. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences.

	Reportable Segments
(in thousands)	Biodefense			Biosciences				All Other				Total
Three Months Ended September 30, 2013
External revenue		$	89,102		$	-			$	-			$	89,102
Net income (loss)			27,175			(12,491	)			(1,193	)			13,491
Three Months Ended September 30, 2012
External revenue		$	66,238		$	354			$	-			$	66,592
Net income (loss)			20,760			(12,165	)			(1,978	)			6,617


	Reportable Segments
(in thousands)	Biodefense			Biosciences				All Other				Total
Nine Months Ended September 30, 2013
External revenue		$	213,663		$	975			$	-			$	214,638
Net income (loss)			56,780			(38,019	)			(2,848	)			15,913
Nine Months Ended September 30, 2012
External revenue		$	181,838		$	5,444			$	-			$	187,282
Net income (loss)			59,361			(47,019	)			(4,925	)			7,417

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Summary of significant accounting policies (Policies)	9 Months Ended
Summary of significant accounting policies (Policies)	Sep. 30, 2013
Summary of significant accounting policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2013 and the results of operations, comprehensive income and cash flows for the three and nine months ended September 30, 2013 and 2012. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC, during the three and nine months ended September 30, 2013, except for the addition of the Company's policy for multiple element revenue-generating arrangements and its revenue recognition policy related to the Company's contract with the Biomedical Advanced Research and Development Authority ("BARDA") to establish a Center for Innovation in Advanced Development and Manufacturing ("CIADM") and the addition of a policy for contingent purchase consideration obligations.
Revenue recognition	Revenue recognition The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's selling price and is recognized in full when the criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company. The Company's contract with the BARDA to establish a CIADM is a service arrangement that includes multiple elements. The CIADM contract requires the Company to provide a flexible infrastructure to supply medical countermeasures to the U.S. government over the contract period and includes such items as construction and facility design, workforce development and licensure of a pandemic flu vaccine. Since none of the individual elements by themselves satisfy the purpose of the contract, the Company has concluded that the CIADM contract elements cannot be separated as they do not have stand-alone value to the U.S. government. Therefore, the Company has concluded that there is a single unit of accounting associated with the CIADM contract. The Company recognizes revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzes the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue is required. Changes in estimates attributed to modifications in the estimate of total payments to be received are recorded prospectively.
Contingent purchase consideration obligations	Contingent purchase consideration obligations In accordance with the terms of the Company's August 2013 acquisition of the Healthcare Protective Products Division ("HPPD"), a division of Bracco Diagnostics Inc. ("Bracco"), the Company has committed to make potential payments to Bracco based on achievement of certain net sales thresholds of RSDL through 2028. The Company records this obligation at fair value. Contingent purchase consideration is based on a percentage of future net RSDL sales. The fair value model used to calculate this obligation is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales. The inputs the Company uses for determining the fair value of the contingent purchase consideration are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales. Any future increase in the fair value of the contingent purchase consideration obligation is based on an increased likelihood that the underlying net sales will be achieved and the associated payment or payments which will therefore become due and payable, which will result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of the contingent purchase consideration obligation will result in a reduction in cost of product sales.

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References + Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Acquisition of Healthcare Protective Products Division (Tables)

9 Months Ended

Sep. 30, 2013

Acquisition of Healthcare Protective Products Division [Abstract]

Schedule of Preliminary Purchase Price

The total preliminary purchase price is summarized below:

(in thousands)
Amount of cash paid to Bracco Diagnostics Inc.	$	24,120
Fair value of contingent purchase consideration		16,232
Total estimated purchase price	$	40,352

Schedule of Purchase Price Allocation

(in thousands)
Acquired intangible assets	$	31,549
Goodwill		8,792
Other		11
Total estimated purchase price	$	40,352

Fair value measurements (Tables)

9 Months Ended

Sep. 30, 2013

Fair value measurements [Abstract]

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At September 30, 2013
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)	$	32,723	$	-	$	-	$	32,723
Total assets	$	32,723	$	-	$	-	$	32,723

Liabilities:
Contingent purchase consideration	$	-	$	-	$	16,581	$	16,581
Total liabilities	$	-	$	-	$	16,581	$	16,581

	At December 31, 2012
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)	$	42,720	$	-	$	-	$	42,720
Total assets	$	42,720	$	-	$	-	$	42,720

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

(in thousands)
Balance at January 1, 2012	$	4,753
Expense (income) included in earnings		(3,005	)
Expense (income) included in comprehensive income (loss)		-
Settlements		(1,748	)
Purchases, sales, issuances and settlements		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2012	$	-
Expense included in earnings		349
Expense (income) included in comprehensive income (loss)		-
Settlements		-
Purchases, sales and issuances		16,232
Transfers in/(out) of Level 3		-
Balance at September 30, 2013	$	16,581

Inventories (Tables)

9 Months Ended

Sep. 30, 2013

Inventories [Abstract]

Inventories

Inventories consist of the following:

	September 30,		December 31,
(in thousands)	2013		2012
Raw materials and supplies	$	2,353	$	2,733
Work-in-process		7,299		9,813
Finished goods		6,673		2,615
Total inventories	$	16,325	$	15,161

Stockholders' equity (Tables)

9 Months Ended

Sep. 30, 2013

Stockholders' equity [Abstract]

Option award activity

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		3,550,842		$	17.07		53,156	$	8.86	$	4,801,378
Granted		926,610			14.84		-
Exercised		(185,173	)		11.57		-
Forfeited		(392,588	)		18.53		-
Outstanding at September 30, 2013		3,899,691		$	16.66		53,156	$	8.86	$	12,844,035
Exercisable at September 30, 2013		2,363,426		$	16.92		53,156	$	8.86	$	7,580,433

Restricted stock units activity

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		715,609		$	18.41	$	11,478,368
Granted		463,304			14.84
Vested		(329,877	)		14.81
Forfeited		(70,896	)		15.84
Outstanding at September 30, 2013		778,140		$	16.33	$	14,823,567

Variable interest entities (Tables)

9 Months Ended

Sep. 30, 2013

Variable interest entities [Abstract]

Schedule of Variable Interest Entities [Table Text Block]

The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:

	Emergent		Noncontrolling
(in thousands)	BioSolutions Inc.		Interests			Total
Stockholders' equity at December 31, 2012	$	441,358	$	770		$	442,128
Non-cash development expenses from variable interest entities		-		(348	)		(348	)
Net income (loss)		15,913		(871	)		15,042
Other		10,035		-			10,035
Stockholders' equity at September 30, 2013	$	467,306	$	(449	)	$	466,857

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

Restructuring (Tables)

9 Months Ended

Sep. 30, 2013

Restructuring [Abstract]

Costs of the restructuring

	Incurred during		Incurred during
	the three months		the nine months		Total Expected
(in thousands)	ended September 30, 2013		ended September 30, 2013		to be Incurred
Termination benefits	$	-	$	2,114	$	2,114
Contract termination costs		-		431		431
Other costs		-		261		261
Total	$	-	$	2,806	$	2,806

Summary of the activity for liabilities related to EPDU restructuring

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

				Contract
	Termination			Termination			Other
(in thousands)	Benefits			Costs			Costs			Total
Balance at December 31, 2012	$	-		$	-		$	-		$	-
Expenses incurred		2,114			431			134			2,679
Amount paid		(1,660	)		(431	)		(134	)		(2,225	)
Other adjustments		-			-			-			-
Balance at September 30, 2013	$	454		$	-		$	-		$	454

Earnings per share (Tables)

9 Months Ended

Sep. 30, 2013

Earnings per share [Abstract]

Summary of basic and diluted net income per share

The following table presents the calculation of basic and diluted net income per share:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except share and per share data)	2013		2012		2013		2012
Numerator:
Net income	$	13,491	$	6,617	$	15,913	$	7,417

Denominator:
Weighted-average number of shares—basic		36,272,579		36,202,801		36,129,183		36,144,242
Dilutive securities—equity awards		742,950		467,293		375,047		280,388
Weighted-average number of shares—diluted		37,015,529		36,670,094		36,504,230		36,424,630

Income per share-basic	$	0.37	$	0.18	$	0.44	$	0.21
Income per share-diluted	$	0.36	$	0.18	$	0.44	$	0.20

Segment information (Tables)

9 Months Ended

Sep. 30, 2013

Segment information [Abstract]

Segment information

12. Segment information

	Reportable Segments
(in thousands)	Biodefense			Biosciences				All Other				Total
Three Months Ended September 30, 2013
External revenue		$	89,102		$	-			$	-			$	89,102
Net income (loss)			27,175			(12,491	)			(1,193	)			13,491
Three Months Ended September 30, 2012
External revenue		$	66,238		$	354			$	-			$	66,592
Net income (loss)			20,760			(12,165	)			(1,978	)			6,617


	Reportable Segments
(in thousands)	Biodefense			Biosciences				All Other				Total
Nine Months Ended September 30, 2013
External revenue		$	213,663		$	975			$	-			$	214,638
Net income (loss)			56,780			(38,019	)			(2,848	)			15,913
Nine Months Ended September 30, 2012
External revenue		$	181,838		$	5,444			$	-			$	187,282
Net income (loss)			59,361			(47,019	)			(4,925	)			7,417

- Definition

+ References

+ Details

Acquisition of Healthcare Protective Products Division (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Aug. 01, 2013	Dec. 31, 2012
Purchase Price Allocation [Abstract]
Goodwill	$ 14,294,000	$ 14,294,000		$ 5,502,000
HPPD [Member]
Business Acquisition [Line Items]
Remaining HPPD assets acquired			$ 1,800,000
Purchase Price [Abstract]
Amount of cash paid to Bracco Diagnostics, Inc.			24,120,000
Fair value of contingent purchase consideration			16,232,000
Total estimated purchase price			40,352,000
Purchase Price Allocation [Abstract]
Acquired intangible assets			31,549,000
Goodwill			8,792,000
Other			11,000
Total estimated purchase price			40,352,000
Business Entity Acquisition Purchase Price			40,352,000
Amortization for intangible assets	779,000	779,000
Acquisition transaction costs	$ 283,000	$ 800,000
HPPD [Member] \| RSDL [Member]
Purchase Price Allocation [Abstract]
Acquired intangible assets			28,100,000
HPPD [Member] \| Manufacturing Agreement [Member]
Purchase Price Allocation [Abstract]
Acquired intangible assets			$ 3,500,000
Contingentconsiderationlowrange [Member]
Business Acquisition [Line Items]
Contingent consideration, percentage of RSDL net sales (in hundredths)			5.00%
Contingentconsidertaionrange [Member]
Business Acquisition [Line Items]
Contingent consideration, percentage of RSDL net sales (in hundredths)			10.00%

Fair value measurements (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
Fair value measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Assets:
Investment in money market funds (1)	$ 32,723	$ 42,720
Total assets	32,723	42,720
Liabilities:
Contingent purchase consideration	16,581
Total liabilities	16,581
Unobservable Input Reconciliation [Roll Forward]
Balance beginning of period	0	4,753
Expense (income) included in earnings	349	(3,005)
Expense (income) included in comprehensive income (loss)	0	0
Settlements	0	(1,748)
Purchases, sales, issuances and settlements	16,232	0
Transfers in/(out) of Level 3	0	0
Balance End of period	16,581	0
Fair Value, Inputs, Level 1 [Member]
Assets:
Investment in money market funds (1)	32,723	42,720
Total assets	32,723	42,720
Liabilities:
Contingent purchase consideration	0
Total liabilities	0
Fair Value, Inputs, Level 2 [Member]
Assets:
Investment in money market funds (1)	0	0
Total assets	0	0
Liabilities:
Contingent purchase consideration	0
Total liabilities	0
Fair Value, Inputs, Level 3 [Member]
Assets:
Investment in money market funds (1)	0	0
Total assets	0	$ 0
Liabilities:
Contingent purchase consideration	16,581
Total liabilities	$ 16,581

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Inventories [Abstract]
Raw materials and supplies	$ 2,353	$ 2,733
Work-in-process	7,299	9,813
Finished goods	6,673	2,615
Total inventories	$ 16,325	$ 15,161

In-process research and development and goodwill (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
In-process research and development and goodwill [Abstract]
Impairment of IPR&D assets	$ 9,600
Goodwill [Line Items]
Goodwill		$ 14,294	$ 5,502
Biosciences [Member]
Goodwill [Line Items]
Goodwill		$ 5,500	$ 5,500

Stockholders' equity (Details) - USD ($)	9 Months Ended
Stockholders' equity (Details) - USD ($)	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Preferred stock
Preferred stock, shares authorized (in shares)	15,000,000		15,000,000
Preferred stock, par value (in dollars per share)	$ 0.001		$ 0.001
Common stock
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001
Common stock, shares authorized (in shares)	100,000,000		100,000,000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 8,459,000	$ 8,417,000
Aggregate intrinsic value [Abstract]
Quantifying Misstatement in Current Year Financial Statements, Amount		$ 3,000,000
Stock Options [Member]
Aggregate Intrinsic Value [Abstract]
Outstanding, beginning of period	4,801,378
Outstanding, end of period	12,844,035
Exercisable, end of period	$ 7,580,433
Restricted Stock Units (RSUs) [Member]
Restricted stock unit award activity [Roll Forward]
Outstanding, beginning of period (in shares)	715,609
Granted (in shares)	463,304
Vested (in shares)	(329,877)
Forfeited (in shares)	(70,896)
Outstanding, end of period (in shares)	778,140
Weighted-Average Grant Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 18.41
Granted (in dollars per share)	14.84
Vested (in dollars per share)	14.81
Forfeited (in dollars per share)	15.84
Outstanding, end of period (in dollars per share)	$ 16.33
Aggregate intrinsic value [Abstract]
Outstanding, beginning of period	$ 11,478,368
Outstanding, end of period	$ 14,823,567
2006 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	3,550,842
Granted (in shares)	926,610
Exercised (in shares)	(185,173)
Forfeited (in shares)	(392,588)
Outstanding, end of period (in shares)	3,899,691
Exercisable, end of period (in shares)	2,363,426
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 17.07
Granted (in dollars per share)	14.84
Exercised (in dollars per share)	11.57
Forfeited (in dollars per share)	18.53
Outstanding, end of period (in dollars per share)	16.66
Exercisable, end of period (in dollars per share)	$ 16.92
2004 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	53,156
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding, end of period (in shares)	53,156
Exercisable, end of period (in shares)	53,156
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 8.86
Outstanding, end of period (in dollars per share)	8.86
Exercisable, end of period (in dollars per share)	$ 8.86

Variable interest entities (Details) - USD ($)	3 Months Ended		9 Months Ended
Variable interest entities (Details) - USD ($)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Variable Interest Entity [Line Items]
Net loss	$ 13,491,000	$ 5,620,000	$ 15,042,000	$ 3,141,000
Oxford Emergent Tuberculosis Consortium [Member]
Variable Interest Entity [Line Items]
Ownership percentage of variable interest entity (in hundredths)			51.00%
Assets	308,000	1,600,000	$ 308,000	1,600,000
Liabilities	$ 243,000	2,800,000	243,000	2,800,000
Net loss		2,000,000	1,800,000	8,500,000
Net losses included in the Company's consolidated statement of operations		$ 1,000,000	$ 905,000	$ 4,300,000

Variable interest entities, summary of the stockholders' equity attributable to the Company and the noncontrolling interests (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity at December 31, 2012			$ 442,128
Non-cash development expenses from variable interest entities			(348)
Net income (loss)	$ 13,491	$ 5,620	15,042	$ 3,141
Other			10,035
Stockholders' equity at September 30, 2013	466,857		466,857
Emergent BioSolutions Inc. [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity at December 31, 2012			441,358
Non-cash development expenses from variable interest entities			0
Net income (loss)			15,913
Other			10,035
Stockholders' equity at September 30, 2013	467,306		467,306
Noncontrolling Interests [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' equity at December 31, 2012			770
Non-cash development expenses from variable interest entities			(348)
Net income (loss)			(871)
Other			0
Stockholders' equity at September 30, 2013	$ (449)		$ (449)

Collaboration Agreements (Details) - USD ($)	3 Months Ended		9 Months Ended
Collaboration Agreements (Details) - USD ($)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Collaborative arrangements [Line Items]
Contracts and grants revenue	$ 12,805,000	$ 12,581,000	$ 42,386,000	$ 45,753,000
Abbott Laboratories TRU016 [Member]
Collaborative arrangements [Line Items]
Revenues related to collaborative research funding				2,700,000
Pfizer CD20 [Member]
Collaborative arrangements [Line Items]
Contracts and grants revenue		$ 356,000		$ 1,200,000

Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2013
Summary of activity for liabilities [Roll Forward]
Balance at December 31, 2012		$ 0	$ 0
Expenses incurred		2,679
Amount paid		(2,225)
Other adjustments		0
Balance at September 30, 2013	$ 454	454
Restructuring expenses		2,679
EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred as of September 30, 2013	0
Inception to date costs incurred		2,806	2,806
Total expected to be incurred		2,806	2,806
Termination benefits [Member]
Summary of activity for liabilities [Roll Forward]
Balance at December 31, 2012		0	0
Expenses incurred		2,114
Amount paid		(1,660)
Other adjustments		0
Balance at September 30, 2013	454	454
Restructuring expenses		2,114
Termination benefits [Member] \| EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred as of September 30, 2013	0
Inception to date costs incurred		2,114	2,114
Total expected to be incurred		2,114	2,114
Contract termination costs [Member]
Summary of activity for liabilities [Roll Forward]
Balance at December 31, 2012		0	0
Expenses incurred		431
Amount paid		(431)
Other adjustments		0
Balance at September 30, 2013	0	0
Restructuring expenses		431
Contract termination costs [Member] \| EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred as of September 30, 2013	0
Inception to date costs incurred		431	431
Total expected to be incurred		431	431
Other costs [Member]
Summary of activity for liabilities [Roll Forward]
Balance at December 31, 2012		0	0
Expenses incurred		134
Amount paid		(134)
Other adjustments		0
Balance at September 30, 2013	0	0
Restructuring expenses		134
Other costs [Member] \| EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred as of September 30, 2013	$ 0
Inception to date costs incurred		261	261
Total expected to be incurred		$ 261	$ 261

Business Interruption Insurance Recovery (Details) $ in Millions	9 Months Ended
	Sep. 30, 2012 USD ($)
Business Interruption Insurance Recovery [Abstract]
BusinessInterruptionInsuranceRevenue	$ 1.7

Earnings per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:
Net income	$ 13,491	$ 6,617	$ 15,913	$ 7,417
Denominator:
Weighted-average number of shares-basic	36,272,579	36,202,801	36,129,183	36,144,242
Dilutive securities-equity awards (in shares)	742,950	467,293	375,047	280,388
Weighted-average number of shares-diluted (in shares)	37,015,529	36,670,094	36,504,230	36,424,630
Income per share-basic	$ 0.37	$ 0.18	$ 0.44	$ 0.21
Income per share-diluted	$ 0.36	$ 0.18	$ 0.44	$ 0.20
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation (in shares)	1,400,000	3,000,000	1,500,000	2,900,000

Segment information (Details) $ in Thousands	3 Months Ended		9 Months Ended
Segment information (Details) $ in Thousands	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)
Segment Reporting Information [Line Items]
Number of business segments			2
External revenue	$ 89,102	$ 66,592	$ 214,638	$ 187,282
Research and development	28,937	27,390	89,939	84,281
Interest revenue	88	55	121	103
Interest expense	0	0	(14)	0
Depreciation and amortization			13,547	7,679
Net income	13,491	6,617	15,913	7,417
In-process research and development assets	41,800		41,800		$ 41,800
Goodwill	14,294		14,294		5,502
Total assets	595,464		595,464		564,230
Biodefense [Member]
Segment Reporting Information [Line Items]
External revenue	89,102	66,238	213,663	181,838
Net income	27,175	20,760	56,780	59,361
Biosciences [Member]
Segment Reporting Information [Line Items]
External revenue	0	354	975	5,444
Net income	(12,491)	(12,165)	(38,019)	(47,019)
Goodwill	5,500		5,500		$ 5,500
All Other [Member]
Segment Reporting Information [Line Items]
External revenue	0	0	0	0
Net income	$ (1,193)	$ (1,978)	$ (2,848)	$ (4,925)